Taysha Gene Therapies (NASDAQ:TSHA) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research report report published on Monday,Benzinga reports. Needham & Company LLC currently has a $6.00 price objective on the stock.

Other equities research analysts also recently issued reports about the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Canaccord Genuity Group raised their price objective on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Chardan Capital reiterated a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. Finally, JMP Securities restated a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, Taysha Gene Therapies currently has an average rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Stock Performance

Shares of TSHA stock opened at $2.05 on Monday. The company has a fifty day moving average price of $2.10 and a two-hundred day moving average price of $2.15. Taysha Gene Therapies has a one year low of $1.19 and a one year high of $4.32. The stock has a market cap of $420.13 million, a P/E ratio of 3.25 and a beta of 0.95. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51.

Institutional Trading of Taysha Gene Therapies

Several institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its position in Taysha Gene Therapies by 23.7% during the 3rd quarter. Geode Capital Management LLC now owns 3,562,758 shares of the company’s stock worth $7,163,000 after buying an additional 682,273 shares during the period. State Street Corp increased its position in Taysha Gene Therapies by 4.5% during the third quarter. State Street Corp now owns 3,469,068 shares of the company’s stock worth $6,973,000 after acquiring an additional 150,647 shares during the period. JPMorgan Chase & Co. raised its stake in Taysha Gene Therapies by 1.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,001,397 shares of the company’s stock worth $6,033,000 after purchasing an additional 37,844 shares in the last quarter. Quantum Private Wealth LLC raised its stake in Taysha Gene Therapies by 5.1% in the 3rd quarter. Quantum Private Wealth LLC now owns 767,616 shares of the company’s stock worth $1,543,000 after purchasing an additional 37,096 shares in the last quarter. Finally, Wellington Management Group LLP bought a new stake in Taysha Gene Therapies in the 3rd quarter valued at about $931,000. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.